Status:
COMPLETED
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
Lead Sponsor:
Pfizer
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or metastatic breast...
Eligibility Criteria
Inclusion
- Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease.
- Tumors over-expressing Her-2
- Candidate for treatment with docetaxel/trastuzumab
Exclusion
- Histology of inflammatory carcinoma
- AST and/or ALT \>1.5 x ULN concomitant with ALP \>2.5 x ULN
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00372424
Start Date
December 1 2006
End Date
September 1 2011
Last Update
December 28 2012
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, 1000
2
Pfizer Investigational Site
Brussels, Belgium, 1200
3
Pfizer Investigational Site
Charleroi, Belgium, 6000
4
Pfizer Investigational Site
Sint-Niklaas, Belgium, 9100